Pro-inflammatory chemokines could potentially serve as diagnostic or prognostic biomarkers in the context of obesity and its complications, and potential chemokine inhibitors (including MCP-1 or the CCR2) could represent a new class of drugs. This evidence concerns the gene CCR2 and Obesity.